GET IN TOUCH

Aragen’s Biologics D&M platform provides integrated gene-to-GMP support across cell line development, process and analytical development, and clinical and commercial GMP manufacturing. The platform combines Aragen’s US-based biologics R&D and cell line development capabilities with process development, analytical laboratories and GMP manufacturing infrastructure in India.

As of 31 March 2026, Aragen had delivered over 200 cell lines to customers, including four commercial launches based on Aragen cell lines, and its installed GMP manufacturing capacity for Biologics D&M was 2.50 KL, supported by upstream process development and quality-control capabilities. 

Aragen’s biologics R&D facility in California has been in operation for over 20 years as of 31 March 2026.

Process Research & Development

Expertise in the complexities and opportunities to accelerate the development of upstream, downstream, and analytical methods.

Bioproduction

Creating R&D cost efficiency with protein and cell reagents.

Developability & Analytics

A broad range of analytical services and capabilities to enable successful biologics characterization and process development in a phase-appropriate manner.

GMP Manufacturing

Meeting your cGMP clinical drug substance needs using our scale-up experience in single-use bioreactors.